Samantha Molsberry1, Kjetil Bjornevik2, Katherine C Hughes2, Zhongli Joel Zhang2, Sarah Jeanfavre3, Clary Clish3, Brian Healy4, Michael Schwarzschild5, Alberto Ascherio5,6,7. 1. Population Health Sciences Program, Harvard University, Cambridge, MA, USA. 2. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3. Metabolomics Platform, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. 4. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 6. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 7. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Although there is evidence of shared dysregulated pathways between diabetes and Parkinson's disease, epidemiologic research on an association between the two diseases has produced inconsistent results. OBJECTIVE: We aimed to assess whether known metabolomic markers of insulin resistance and diabetes are also associated with Parkinson's disease development. METHODS: We conducted a nested case-control study among Nurses' Health Study and Health Professionals Follow-up Study participants who had provided blood samples up to twenty years prior to Parkinson's diagnosis. Cases were matched to risk-set sampled controls by age, sex, fasting status, and time of blood collection. Participants provided covariate information via regularly collected cohort questionnaires. We used conditional logistic regression models to assess whether plasma levels of branched chain amino acids, acylcarnitines, glutamate, or glutamine were associated with incident development of Parkinson's disease. RESULTS: A total of 349 case-control pairs were included in this analysis. In the primary analyses, none of the metabolites of interest were associated with Parkinson's disease development. In investigations of the association between each metabolite and Parkinson's disease at different time intervals prior to diagnosis, some metabolites showed marginally significant association but, after correction for multiple testing, only C18 : 2 acylcarnitine was significantly associated with Parkinson's disease among subjects for whom blood was collected less than 60 months prior to case diagnosis. CONCLUSIONS: Plasma levels of diabetes-related metabolites did not contribute to predict risk of Parkinson's disease. Further investigation of the relationship between pre-diagnostic levels of diabetes-related metabolites and Parkinson's disease in other populations is needed to confirm these findings.
BACKGROUND: Although there is evidence of shared dysregulated pathways between diabetes and Parkinson's disease, epidemiologic research on an association between the two diseases has produced inconsistent results. OBJECTIVE: We aimed to assess whether known metabolomic markers of insulin resistance and diabetes are also associated with Parkinson's disease development. METHODS: We conducted a nested case-control study among Nurses' Health Study and Health Professionals Follow-up Study participants who had provided blood samples up to twenty years prior to Parkinson's diagnosis. Cases were matched to risk-set sampled controls by age, sex, fasting status, and time of blood collection. Participants provided covariate information via regularly collected cohort questionnaires. We used conditional logistic regression models to assess whether plasma levels of branched chain amino acids, acylcarnitines, glutamate, or glutamine were associated with incident development of Parkinson's disease. RESULTS: A total of 349 case-control pairs were included in this analysis. In the primary analyses, none of the metabolites of interest were associated with Parkinson's disease development. In investigations of the association between each metabolite and Parkinson's disease at different time intervals prior to diagnosis, some metabolites showed marginally significant association but, after correction for multiple testing, only C18 : 2 acylcarnitine was significantly associated with Parkinson's disease among subjects for whom blood was collected less than 60 months prior to case diagnosis. CONCLUSIONS: Plasma levels of diabetes-related metabolites did not contribute to predict risk of Parkinson's disease. Further investigation of the relationship between pre-diagnostic levels of diabetes-related metabolites and Parkinson's disease in other populations is needed to confirm these findings.
Authors: S E Hankinson; W C Willett; J E Manson; G A Colditz; D J Hunter; D Spiegelman; R L Barbieri; F E Speizer Journal: J Natl Cancer Inst Date: 1998-09-02 Impact factor: 13.506
Authors: M J Stampfer; W C Willett; F E Speizer; D C Dysert; R Lipnick; B Rosner; C H Hennekens Journal: Am J Epidemiol Date: 1984-05 Impact factor: 4.897
Authors: Marta Guasch-Ferré; Yan Zheng; Miguel Ruiz-Canela; Adela Hruby; Miguel A Martínez-González; Clary B Clish; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Courtney Dennis; Isabel M Morales-Gil; Fernando Arós; Miquel Fiol; José Lapetra; Lluís Serra-Majem; Frank B Hu; Jordi Salas-Salvadó Journal: Am J Clin Nutr Date: 2016-04-20 Impact factor: 7.045
Authors: Mary K Townsend; Clary B Clish; Peter Kraft; Chen Wu; Amanda L Souza; Amy A Deik; Shelley S Tworoger; Brian M Wolpin Journal: Clin Chem Date: 2013-07-29 Impact factor: 8.327
Authors: Sean H Adams; Charles L Hoppel; Kerry H Lok; Ling Zhao; Scott W Wong; Paul E Minkler; Daniel H Hwang; John W Newman; W Timothy Garvey Journal: J Nutr Date: 2009-04-15 Impact factor: 4.798
Authors: A M Wolf; D J Hunter; G A Colditz; J E Manson; M J Stampfer; K A Corsano; B Rosner; A Kriska; W C Willett Journal: Int J Epidemiol Date: 1994-10 Impact factor: 7.196